In:
International Journal of Cancer, Wiley, Vol. 141, No. 7 ( 2017-10), p. 1422-1433
Abstract:
What's new? p53 mutation is rarely detected in ccRCC, but these tumors are highly resistant to chemotherapies. Here, the authors found that ASPP1 suppression is significantly associated with higher grade and poorer survival of ccRCC. Restore ASPP1 inhibits ccRCC proliferation, and also improves ccRCC's sensitivity to the conventional chemotherapeutic drug 5‐FU via specifically activating p53's transcriptional activities toward apoptosis. The findings provide insight into the capability of ASPP1 for overcoming ccRCC resistance by re‐activating p53‐dependent pro‐apoptosis activity.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2017
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8